The role of omentectomy in the surgical management of mucinous and serous borderline ovarian tumors

Background: This systematic review evaluates the role of omentectomy in borderline ovarian tumors (BOTs), particularly mucinous BOTs (mBOTs). Considering the differences in the prevalence of omental disease between serous BOTs (sBOTs) and mBOTs, the necessity of omentectomy in mBOTs is controversial. Methods: A systematic literature search was conducted using two electronic databases—PubMed and Scopus—following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines. Studies providing data on omentectomy in BOTs were included in this review. Results: A total of 40 studies involving over 7000 patients were included. Among the 37 studies that reported performing omentectomy, 19 (51.4%) reported the presence of omental disease: with sBOT in 15 studies (78.9%) and with mBOT in 3 studies (15.8%) and the rest did not report the BOT subtype. The highest rate of omental disease in mBOT patients was reported at 5.4% in one study. No cases of upstaging due to omental involvement were observed in mBOT patients. Also, the prevalence of peritoneal implants seem to be higher in sBOTs than in mBOTs. The impact of omentectomy on recurrence and survival varied between studies. The higher recurrence rates are reported among patients undergoing fertility-sparing surgery but no significant difference in survival is seen. Conclusions: Omentectomy may not be necessary for mBOT patients due to the low risk of omental disease. Omentectomy remains essential for sBOT patients due to the higher risk of extra-ovarian disease in the omentum. The PROSPERO Registration: CRD420251139223.

Borderline ovarian tumors; Omentectomy; Serous borderline ovarian tumors; Mucinous borderline ovarian tumors; Surgical staging

[1] Qi Y, Wang M, Yang Y, Zeng Z, Zhou Y. Analysis of factors influencing relapse and pregnancy in patients with borderline ovarian tumors. Journal of Cancer. 2021; 12: 5275–5285.

[2] Bendifallah S, Nikpayam M, Ballester M, Uzan C, Fauvet R, Morice P, et al. New pointers for surgical staging of borderline ovarian tumors. Annals of Surgical Oncology. 2016; 23: 443–449.

[3] Cheung A, Ellenson LH, Gilks CB. Tumours of the ovary. In WHO Classification of Tumours Editorial Board (ed.) WHO classification of tumours: female genital tumours (pp. 31–167). 5th edn. International Agency for Research on Cancer: Lyon, France. 2020.

[4] Kristensen GS, Schledermann D, Mogensen O, Jochumsen KM. The value of random biopsies, omentectomy, and hysterectomy in operations for borderline ovarian tumors. International Journal of Gynecological Cancer. 2014; 24: 874–879.

[5] Guo L, Kang X, Su Y, Liu X, Wu X, Xie W, et al. Is there re-staging surgery necessity for borderline ovarian tumors. Current Medical Science. 2023; 43: 822–830.

[6] Daraï E, Tulpin L, Prugnolle H, Cortez A, Dubernard G. Laparoscopic restaging of borderline ovarian tumors. Surgical Endoscopy. 2007; 21: 2039–2043.

[7] Raimondo D, Raffone A, Zakhari A, Maletta M, Vizzielli G, Restaino S, et al. The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: a systematic review and meta-analysis. Gynecologic Oncology. 2022; 165: 184–191.

[8] Skala SL, Hagemann IS. Optimal sampling of grossly normal omentum in staging of gynecologic malignancies. International Journal of Gynecological Pathology. 2015; 34: 281–287.

[9] Kavak Cömert D, Ureyen I, Karalok A, Tasci T, Turkmen O, Ocalan R, et al. Mucinous borderline ovarian tumors: analysis of 75 patients from a single center. Journal of the Turkish German Gynecological Association. 2016; 17: 96–100.

[10] De Decker K, Speth S, Ter Brugge HG, Bart J, Massuger LFAG, Kleppe M, et al. Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease. Gynecologic Oncology. 2017; 144: 285–289.

[11] Colombo N, Sessa C, Bois A du, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology. 2019; 30: 672–705.

[12] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ. 2021; 372: n71.

[13] Joanna Briggs Institute. Checklist for cohort studies. 2025. Available at: https://jbi.global/sites/default/files/2020-08/Checklist_for_Cohort_Studies.pdf (Accessed: 13 February 2025).

[14] Joanna Briggs Institute. Checklist for case series studies. 2025. Available at: https://jbi.global/sites/default/files/2020-08/Checklist_for_Case_Series.pdf (Accessed 13 February 2025).

[15] Kærn J, Tropé CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian radium hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer. 1993; 71: 1810–1820.

[16] Camatte S, Morice P, Thoury A, Fourchotte V, Pautier P, Lhomme C, et al. Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 cases. European Journal of Cancer. 2004; 40: 1842–1849.

[17] Damak T, Ben Hassouna J, Chargui R, Gamoudi A, Hechiche M, Dhieb T, et al. Borderline tumors of the ovary. La Tunisie Médicale. 2014; 92: 411–416.

[18] Deffieux X, Morice P, Camatte S, Fourchotte V, Duvillard P, Castaigne D. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants. Gynecologic Oncology. 2005; 97: 84–89.

[19] Doig T, Monaghan H. Sampling the omentum in ovarian neoplasia: when one block is enough. International Journal of Gynecological Cancer. 2006; 16: 36–40.

[20] Falcone F, Breda E, Ferrandina G, Malzoni M, Perrone AM, Cormio G, et al. Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database. Gynecologic Oncology. 2021; 161: 825–831.

[21] Falcone F, Malzoni M, Carnelli M, Cormio G, De Iaco P, Di Donato V, et al. Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: analysis from the MITO14 study database. Gynecologic Oncology. 2022; 165: 302–308.

[22] Fotopoulou C, Schumacher G, Schefold JC, Denkert C, Lichtenegger W, Sehouli J. Systematic evaluation of the intraoperative tumor pattern in patients with borderline tumor of the ovary. International Journal of Gynecological Cancer. 2009; 19: 1550–1555.

[23] Gungorduk K, Asicioglu O, Braicu EI, Almuheimid J, Gokulu SG, Cetinkaya N, et al. The impact of surgical staging on the prognosis of mucinous borderline tumors of the ovaries: a multicenter study. Anticancer Research. 2017; 37: 5609–5616.

[24] Gungor T, Cetinkaya N, Yalcin H, Ozdal B, Ozgu E, Baser E, et al. Is target oriented surgery sufficient with borderline ovarian tumors?—Role of accompanying pathologies. Asian Pacific Journal of Cancer Prevention. 2014; 15: 6749–6754.

[25] Guvenal T, Dursun P, Hasdemir PS, Hanhan M, Guven S, Yetimalar H, et al. Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish gynecologic oncology group study. Gynecologic Oncology. 2013; 131: 546–550.

[26] He Y, Zhong J, Yang H, Shan N, Cheng A. Clinical characteristics predict recurrence in borderline ovarian tumor patients with fertility-preserving surgery. International Journal of General Medicine. 2022; 15: 2197–2206.

[27] Jung HJ, Park JY, Kim DY, Suh DS, Kim JH, Kim YM, et al. Low value of staging in detecting extraovarian occult metastasis in mucinous borderline ovarian tumors. International Journal of Gynecological Cancer. 2020; 30: 1780–1783.

[28] Kane A, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P. Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary. Fertility and Sterility. 2010; 94: 2891–2894.

[29] Kumpulainen S, Kuoppala T, Leminen A, Komulainen M, Puistola U, Sankila R, et al. Surgical staging, treatment, and follow‐up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland. Acta Obstetricia et Gynecologica Scandinavica. 2007; 86: 610–614.

[30] Lackman F, Carey MS, Kirk ME, McLachlin CM, Elit L. Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants. Gynecologic Oncology. 2003; 90: 407–412.

[31] Lecointre L, Bund V, Sangnier E, Ouldamer L, Bendifallah S, Koskas M, et al. Status of surgical management of borderline ovarian tumors in France: are recommendations being followed? Multicentric French study by the FRANCOGYN group. Annals of Surgical Oncology. 2021; 28: 7616–7623.

[32] Lin PS, Gershenson DM, Bevers MW, Lucas KR, Burke TW, Silva EG. The current status of surgical staging of ovarian serous borderline tumors. Cancer. 1999; 85: 905–911.

[33] Loizzi V, Selvaggi L, Leone L, Latorre D, Scardigno D, Magazzino F, et al. Borderline epithelial tumors of the ovary: experience of 55 patients. Oncology Letters. 2015; 9: 912–914.

[34] Lu Z, Li B, Gu C. Outcomes of fertility-sparing surgery for stage II and III serous borderline ovarian tumors. Journal of International Medical Research. 2019; 47: 4895–4903.

[35] Menczer J, Chetrit A, Sadetzki S. The effect of hysterectomy on survival of patients with borderline ovarian tumors. Gynecologic Oncology. 2012; 125: 372–375.

[36] Muzii L, Palaia I, Sansone M, Calcagno M, Plotti F, Angioli R, et al. Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies. Fertility and Sterility. 2009; 91: 2632–2637.

[37] Nasioudis D, Alevizakos M, Holcomb K, Witkin SS. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population. Maturitas. 2017; 96: 45–50.

[38] Nezhat FR, Ezzati M, Chuang L, Shamshirsaz AA, Rahaman J, Gretz H. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. American Journal of Obstetrics and Gynecology. 2009; 200: 83.e1–83.e6.

[39] Şahin HO, Yilmaz A, Bayrak M, Pek E, Özerkan K, Ozan H. Recurrence of borderline ovarian tumors: clinical and pathological risk factors. European Journal of Gynaecological Oncology. 2021; 42: 580.

[40] Shih KK, Zhou QC, Aghajanian C, Huh J, Soslow RA, Morgan JC, et al. Patterns of recurrence and role of adjuvant chemotherapy in stage II–IV serous ovarian borderline tumors. Gynecologic Oncology. 2010; 119: 270–273.

[41] Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, et al. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. British Journal of Cancer. 2015; 112: 660–666.

[42] Ureyen I, Karalok A, Tasci T, Turkmen O, Boran N, Tulunay G, et al. The factors predicting recurrence in patients with serous borderline ovarian tumor. International Journal of Gynecological Cancer. 2016; 26: 66–72.

[43] Uzan C, Berretta R, Rolla M, Gouy S, Fauvet R, Darai E, et al. Management and prognosis of endometrioid borderline tumors of the ovary. Surgical Oncology. 2012; 21: 178–184.

[44] Weir MM, Bell DA, Young RH. Grade 1 peritoneal serous carcinomas: a report of 14 cases and comparison with 7 peritoneal serous psammocarcinomas and 19 peritoneal serous borderline tumors. The American Journal of Surgical Pathology. 1998; 22: 849–862.

[45] Westermann T, Karabeg E, Heitz F, Traut A, Plett H, Moubarak M, et al. Role of fertility-sparing surgery and further prognostic factors in borderline tumors of the ovary. International Journal of Gynecological Cancer. 2024; 34: 898–905.

[46] Zilliox M, Lecointre L, Azais H, Ballester M, Bendifallah S, Bolze PA, et al. Management of borderline ovarian tumours during pregnancy: results of a French multi-centre study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021; 256: 412–418.

[47] Martinez-Quinones P, Bass GA. Crosstalk in the abdomen: the interface of the omentum and the microbiome in sepsis. Surgical Infections. 2023; 24: 232–237.

[48] Smit JM, Plat VD, Panday AN, Daams F, Negenborn VL. What are the short- and long-term abdominal consequences of an omentectomy? A systematic review. Journal of Surgical Oncology. 2024; 129: 1420–1429.